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48.3% were part of the public health system and the
remaining 51.7% units were part of the private health
system. The patient survey analysed 758 patients who
were chosen at random from among the aforementioned
78 HD units. Results: A) HD Centre Survey: The majority of
adult HD units (n=61, 70.2%) used both kinds of heparin,
19 of them (21.8%) only used LMWH and 7 of them (8%)
only used UFH. The most frequently applied criteria for the
use of LMWH were medical indications (83.3% of HD
units) and ease of administration (29.5%). The most
frequently used methods for adjusting the dosage were
clotting of the circuit (88.2% of units), bleeding of the
vascular access after disconnection (75.3%), and patient
weight (57.6%). B) Patient Survey: The distribution of the
types of heparin used was: UFH: 44.1%, LMWH: 51.5%,
ABSTRACT
Objectives: The study’s objectives were to determine which
anticoagulation methods are commonly used in patients
who are undergoing haemodialysis (HD) in Spain, on what
criteria do they depend, and the consequences arising
from their use. Material and Method: Ours was a cross-
sectional study based on two types of surveys: a “HD
Centre Survey” and a “Patient Survey”. The first survey
was answered by 87 adult HD units serving a total of 6093
patients, as well as 2 paediatric units. Among these units,
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and dialysis without heparin in 4.4% of patients. LMWH
was more frequently used in public medical centres (64.2%
of patients) than in private medical centres (46.1%)
(P<.001). LMWH was more frequently used in on-line
haemodiafiltration (HF) than in high-flux HD (P<.001).
Antiplatelet agents were given to 45.5% of patients, oral
anticoagulants to 18.4% of patients, and both to 5% of
patients. Additionally, 4.4% of patients had suffered
bleeding complications during the previous week, and
1.9% of patients suffered thrombotic complications.
Bleeding complications were more frequent in patients
with oral anticoagulants (P=.001), although there was no
association between the type of heparin and the
occurrence of bleeding or thrombotic complications.
Conclusions: We are able to conclude that there is a great
amount of disparity in the criteria used for the medical
prescription of anticoagulation in HD. It is advisable that
each HD unit revise their own results as well as those from
other centres, and possibly to create an Anticoagulation
Guide in Haemodialysis.
Key Words: Anticoagulation. Haemodialysis. Heparin. Low
molecular weight heparin. Clotting.
Estudio español sobre anticoagulación en hemodiálisis
RESUMEN
Objetivos: Los objetivos del presente trabajo fueron cono-
cer qué métodos de anticoagulación se emplean en la prác-
tica habitual en los pacientes en hemodiálisis (HD) en Espa-
ña, de qué criterios dependen y las complicaciones
derivadas de su uso. Material y métodos: Es un estudio de
diseño transversal basado en dos tipos de encuestas, una
de centros y otra de pacientes. La primera fue contestada
por 87 unidades de HD de adultos que incluían 6.093 pa-
cientes, y 2 unidades pediátricas; 43 centros (48,3%) eran
de titularidad pública y 46 (51,7%), privada/concertada. En
la encuesta de pacientes se analizaban 758 pacientes elegi-
dos al azar de manera aleatoria en 78 unidades de HD. 
Resultados: A) Encuesta de centros: La mayoría de los cen-
tros de adultos (n = 61, 70,2%) disponían tanto de hepari-
na de bajo peso molecular (HBPM) como de heparina no
fraccionada (HNF), 19 (21,8%) sólo emplean HBPM y 7 (8%)
utilizaban exclusivamente HNF. Las criterios más frecuentes
para el empleo de HBPM fueron indicaciones médicas
(83,3% de los centros) y la comodidad en la administración
(29,5%). Los métodos más empleados para el ajuste de la
dosis eran la coagulación del circuito (88,2% de los centros),
el sangrado del acceso vascular tras la desconexión (75,3%)
y el peso del paciente (57,6%). B) Encuesta de pacientes: La
distribución del tipo de heparina empleada fue: 44,1% HNF,
51,5% HBPM y 4,4% diálisis sin heparina. La HBPM se utili-
za más frecuentemente en los centros públicos (64,2% de
los pacientes) que en los privados/concertados (46,1%) (p <
0,001). La HBPM se utilizaba con mayor frecuencia en la he-
modiafiltración en línea que en la HD de alto flujo (p <
0,001). Un 45,5% de los pacientes recibían antiagregantes,
un 18,4% anticoagulantes orales y un 5% ambos. El 4,4%
de los pacientes tuvo complicaciones hemorrágicas en la úl-
tima semana y el 1,9% complicaciones trombóticas. Las
complicaciones hemorrágicas fueron más frecuentes en los
pacientes que tomaban anticoagulantes orales (p = 0,01).
No había asociación entre el tipo de heparina y las compli-
caciones hemorrágicas. Conclusiones: Se puede concluir
que existe una gran disparidad de criterios en la prescrip-
ción de la anticoagulación en HD. Es aconsejable revisar los
resultados propios y externos, y posiblemente crear una
guía de anticoagulación en hemodiálisis.
Palabras clave: Anticoagulación. Hemodiálisis. Heparina.
Heparina de bajo peso molecular. Coagulación.
INTRODUCTION
In haemodialysis (HD), a common issue arises in the form of
coagulation of the extra-corporeal blood circuit, which must be
prevented, normally by administering heparin. The objective is to
use the lowest possible dose of anticoagulant so as to maintain the
dialyser and venous chamber free from blood cell debris. Another
objective is to be able to quickly achieve haemostasis at the
vascular access points after the session. In general, the doses
applied tend to be lower than the necessary amount for complete
anticoagulation, although these doses vary widely between
patients, and depend on both patient and HD characteristics.1,2 On
the other hand, insufficient anticoagulation therapy can decrease
the effectiveness of dialysis to purify the blood.1,2
Several different issues can arise from applying repeated and
intermittent heparin to patients on HD programmes, which
can involve over 600 cumulative hours per year. These
include risk of bleeding and thrombotic complications
(which are not always correlated with over or under-dosing),
metabolic effects, primarily dyslipidemia, osteoporosis, and
effects on blood cells, especially platelets.1,2
Since the 1980’s, low molecular weight heparin (LMWH)
has been incorporated into daily clinical practice as an
alternative to conventional, or unfractionated heparin (UFH),
with the goal of improving efficacy and safety, reducing the
secondary side effects produced, and facilitating patient
management in terms of dosage adjustments and
administration regimens.3-5 Several different studies have
shown that LMWH and UFH have similar levels of efficacy
and safety.6-7 As regards side effects, studies have shown that
LMWH produces a lower increase in plasma triglyceride
levels8,9 and lower incidences of thrombocytopenia10 and
osteoporosis11 than UFH. The ease of administration, higher
cost, persistence of anticoagulation activity several hours
after the HD session, risk of accumulation using high and
frequent doses, and the complexity of adjusting doses using
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vascular access type, membrane type, dialysis technique,
duration of HD sessions, and blood pump flow. We also asked
if the patient was receiving additional anticoagulant and/or
anti-platelet treatment, as well as whether any bleeding or
thrombotic complications arose in the previous week.
We performed all statistical analyses using SPSS statistical
software, version 15.0. We analysed qualitative variables
using absolute frequencies and percentages, while quantitative
variables were assessed using mean, standard deviation,
median, minimum, and maximum. We applied tests of
normality (Kolmogorov-Smirnov) and homoscedasticity
(Levene) prior to applying parametric tests. We compared
more than 2 groups using one-way ANOVA tests for normally
distributed continuous variables, and Kruskal-Wallis tests for
non-parametric variables. For comparisons of group means,
we used Student’s t-tests in the case of normally distributed
continuous variables, and Mann-Whitney U-tests for non-
parametric variables. In the case of discreet variables, we used
chi-square or Fisher’s exact tests when necessary. Following
these comparisons, we selected those variables with a P-value
<.100 for use in a logistic regression model. The level of
statistical significance was set at 5%.
This study has been approved by the Spanish Society of
Nephrology.
RESULTS
For a better comprehension of the results obtained, we have
separated this section into two parts, corresponding to the
data obtained in the surveys for haemodialysis centres and
the data for patient surveys.
Haemodialysis centre survey
We compiled surveys from 89 haemodialysis centres
throughout the country, constituting 29% of all such centres
in Spain. Of these, 43 (48.3%) were public entities, and 46
(51.7%) were private. Of the 89 centres that responded to the
survey, only 2 were paediatric units, and these were
excluded from the general statistical analysis. The remaining
87 centres corresponded to adult patients, and at the moment
the survey was taken, these centres treated a total of 6093
patients.
The data obtained from these 87 surveys are as follows:
1. Type of heparin
The majority of the centres surveyed (61; 70.2%) utilised
both types of heparin, 19 (21.8%) only administered
LMWH, and 7 (8%) only used UFH. Although there was a
laboratory control tests are also factors to take into account
when prescribing LMWH over UFH. Thus, whereas the
guidelines recommend using LMWH over UFH,12 in current
clinical practice, there is no established consensus for
prescribing one type of heparin or the other.
In addition to the individualisation of the type and dose of
heparin to be used, other aspects of this treatment also lack
standardised criteria, such as system priming with or without
heparin (and if so, the dose to be used), the mode of
administration, and the prescription for anticoagulation
based on the HD technique used. For their part, elderly age
and cardiovascular comorbidity already necessitate oral anti-
platelet and/or anticoagulant treatment in an undetermined
percentage of prevalent HD patients, for which there are no
general recommendations when considering prescribing
anticoagulation therapy during an HD session.
Given the heterogeneity of the possible variables, approaching
to this subject first involves defining the current situation in
clinical practice, that is to say, document which methods are
being applied in the various dialysis centres around the
country. For this reason, the Task Force for Anticoagulation in
Haemodialysis of the Spanish Society of Nephrology (S.E.N.,
for its initials in Spanish) proposed a study based on surveys
completed by all of the haemodialysis units in Spain, with the
objectives of, firstly, assessing which anticoagulation methods
are being used in Spain, secondly, what criteria define which
methods to use, and finally, which method is more commonly
associated with bleeding and thrombotic complications.
MATERIAL AND METHOD
Ours was a cross-sectional descriptive study based on two
different types of surveys: one survey for haemodialysis
centres, and another for patients. The first survey was
designed to evaluate the anticoagulation policies used at
public and private HD centres. The patient survey analysed
individual anticoagulation data from a randomly chosen 10-
patient sample from each centre. The surveys were
distributed and collected between May and September 2008.
The survey for dialysis centres collected information on the
type of heparin used, dose and method of administration, and
circuit priming. The survey also included a section on the
criteria used for deciding whether to administer LMWH or
UFH, with the following possible responses: 1) medical
criteria (dyslipidemia, thrombocytopenia, etc.). 2) Dosing. 3)
Cost. 4) Dialysis technique. 5) Vascular access. 6) Other.
Finally, we asked for information on the adjustment methods
used for dosing UFH and LMWH.
In addition to the questions regarding the anticoagulation
methods used for each patient, the patient survey included
questions on diagnosis of diabetes, haemoglobin levels,
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certain tendency to use LMWH to a greater extent at public
centres than private ones, this difference was not statistically
significant (P=.073). The types of LMWH available at the
80 centres were: enoxaparin (60%), bemiparin (32.6%),
nadroparin (21.3%), dalteparin (12.5%), and tinzaparin
(11.3%).
2. Criteria used for LMWH
This was a multiple choice question, and the percentages for
each response were calculated for the 78 centres that
responded (Table 1).
3. Type of HD priming
There is a wide variability in both the use of heparin priming
and the dose used. We can summarise that:
- If UFH was used during HD (68 centres), the majority
used UFH for priming (86.7%), 7.4% did not use heparin
for priming, and 5.9% did so with or without heparin
depending on the patient.
- If LMWH was used (73 centres), 21.9% of centres did
not use heparin priming, 71.3% did so with heparin, and
6.8% either used or did not use heparin, depending on the
patient.
The heparin dose used for priming ranged between 1000UI
and 10 000UI. However, regardless of the type of heparin
used in the HD session, the most commonly used dose was
5000UI (66% of centres when UFH was used, and 67.6% of
centres when LMWH was used), followed by 2500UI (17%
with UFH, and 16.2% with LMWH).
4. Dosing
The methods of administration employed for heparin doses
are summarised in Figure 1. Regardless of the method of
administration for UFH throughout the HD session, the
majority of centres used an initial bolus (92.6% when using
a continuous dose, 97.6% when using an intermittent dose).
5. Adjustment methods for the heparin dose
We received 85 responses for this section from the 87
surveys sent. As such, the percentages for this question were
calculated over 85, and the results are summarised in Table
2. The general rule was that several factors were taken into
account when adjusting the dose used. This was a multiple
choice question that allowed us to assess the possible
combination of factors in this context. Among these, the
most common combinations used were: “weight +
coagulation of the dialyser/lines + bleeding after disconnect”
in 30 centres (35.3%) and “coagulation of the dialyser/lines
+ bleeding after disconnect” in 17 centres (20%), with all
others being much less common.
Patient survey
Of the 89 centres that responded to our surveys, 80 provided
patient data, with a total of 770 patients surveyed. The
general statistical analysis did not include 12 patients (10
due to non-compliance with the full range of questions asked
at one centre, and 2 who were paediatric patients). In this
manner, a total of 758 adult patients were included in the
analysis from 78 different dialysis centres, of which 34
(43.6%) were public and 44 (56.4%) were private. The most
important characteristics of these patients are summarised in
Table 3.
The most relevant data obtained in the patient survey can be
summarised as:
1. Anticoagulation in the study population
We obtained data on 733 patients, of which 323 (44.1%)
received treatment with UFH, 378 (51.5%) with LMWH,
and 32 (4.4%) received no anticoagulation during dialysis.
At public centres, 64.2% of patients received LMWH,
whereas 46.1% of patients received this type of heparin at
private centres (statistically significant difference; P<.001).
The heparin dose was quantified in 291 patients, 186 of
which received UFH and 105 received LMWH. The mean
dose of UFH was 2988 (1706) UI (range: 500-9500UI,
median: 3000UI) and the mean dose of LMWH was 3598
(1601) UI (range: 1000-8000UI, median: 3500UI).
Table 1. HD centre survey. Criteria for the use of LMWH vs
UFH
No. Centres Percentage
Medical criteria 65 83.3%
Dosing 23 29.5%
Vascular access 19 24.4%
Cost 8 10.3%
Dialysis technique 6 7.7%
Other criteriaa 8 10.3%
a These criteria include: 1) anticoagulation administered to the patient
upon referral from the hospital, 2) availability, 3) machines without
heparin sodium pump, 4) pensioner patients, 5) protocol at the
haemodialysis unit, 6) European guideline recommendations, 
7) pharmacological approach, and 8) manipulation by personnel.
LMWH: low molecular weight heparin; UFH: unfractionated heparin.
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2. Anticoagulation according to patient characteristics
Upon analysis of patient characteristics based on the type
of heparin used, we observed no differences in terms of
sex or prevalence of diabetes. However, patients that
received LMWH tended to be younger, and had lower
haemoglobin levels (Table 3). There were no differences
in the heparin doses prescribed (for both UFH and
LMWH) in terms of age, sex, haemoglobin levels, or
diagnosis of diabetes.
3. Anticoagulation according to vascular access
The distribution of vascular access types in the 758 patients
that responded to this part of the survey was: autologous
arteriovenous fistula (AVF): 68.5%, prosthesis: 7.8%, and
catheter: 23.7%. There were no differences in terms of the
distribution of the different types of vascular access between
public and private centres. In patients with AVF, LMWH was
utilised more frequently (56% vs 44%) whereas patients with
prosthesis were administered UFH more frequently (62% vs
38%) (P=.048). In patients with a catheter, the rates of using
the two types of heparin were similar.
There were no differences in terms of the heparin doses
prescribed (whether for UFH or LMWH) based on the type
of vascular access used.
4. Anticoagulation according to the technique and
membrane type used for dialysis
The dialysis technique used was recorded for 757 patients, of
which 413 (54.6%) received high-flux HD, 249 (32.9%)
received low-flux HD, and 95 (12.5%) received on-line
haemodiafiltration (OL-HDF). At public centres, the
distribution was: high-flux HD: 47.5%, low-flux HD: 30.7%,
Figure 1. HD centre survey. Heparin dosing
Table 2. HD centre survey. Dose adjustment methods
No. centres Percentage
Lee White method 
or total clotting time 10 11.8%
Activated clotting time 0 0
Partial thromboplastin time 7 8.2%
Weight 49 57.6%
Coagulation of the dialyser/lines 75 88.2%
Bleeding after disconnect 64 75.3%
Other
Activated factor X 5 5.9%
Anticoagulant treatment 3 3.5%
Clinical characteristics 2 2.4%
4.5% (3)
35.8% 
(24)
94.9% (74)
5.1% (4)
59.7% 
(40)
Only continuous
Only intermitent
Both
Unfractionated heparin Low molecular weight heparin
Single initial
Initial bolus + others
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and OL-HDF: 21.7%, whereas at private centres, the
distribution was 59.8%, 34.5%, and 5.7%, respectively
(P=.001).
The distribution of the type of heparin used according to the
dialysis technique used is represented in Figure 2.
The types of membranes used for dialysis were: cellulose:
6.1%, polysulfone: 59.5%, polyethersulfone: 12.2%,
polyamide: 15.8%, AN69: 3.7%, and other: 2.7%. We
observed no significant differences in terms of the type of
membrane used between public and private centres. There
were also no significant differences in the type of heparin
administered (UFH vs LMWH) based on membrane type.
The heparin doses prescribed were similar regardless of the
HD technique or membrane type used.
5. Anticoagulation according to time on dialysis and
blood pump flow
The mean duration of HD sessions was 231 (26) minutes
(range: 120-310 minutes), with the most common duration of
sessions being 4:00 and <4:30 hours (n=440; 59.2%), followed
by the interval of 3:30 and <4:00 hours (n=172; 23.1%), and
>4:30 hours (n=63; 8.4%). There was no correlation between
the type of heparin used and the duration of the HD session. As
was expected, the dose of heparin prescribed was significantly
lower in patients with shorter dialysis sessions (less than 4
hours) as compared to sessions lasting >4 hours, both when
employing UFH (2443±1246UI vs 3264±1804UI; P=.003) and
LMWH (2828±1234UI vs 3870±1630UI; P=.002).
Mean blood pump flow was 346 (47) ml/min (range: 150-
500ml/min). Blood pump flow was significantly higher in the
group that received UFH as compared to the group that
received LMWH (351±42ml/min vs 339±51ml/min; P=.001).
6. Anticoagulation in haemodialysis and 
anti-platelet and/or anticoagulant treatment
We acquired survey responses regarding anti-platelet and/or
oral anticoagulant treatment from 727 patients. Of these, 331
(45.5%) received anti-platelets, 134 (18.4%) received oral
anticoagulants, and 36 (5%) received both. Overall, 425
(58.5%) received some type of anti-platelet and/or
anticoagulant treatment.
The majority of patients that received oral anticoagulant
treatment (n=115; 85.8%) also required heparin during HD.
LMWH was used somewhat more frequently in these cases,
although this difference was not statistically significant
(LMWH: 56.4%; UFH: 43.6%). The UFH dose prescribed in
patients that also received coumarin-type drugs was lower
than in those that did not (2279±1499UI vs 3105±1721UI;
P=.012), whereas no significant differences were observed in
the doses prescribed for LMWH (3913±1768UI vs
3439±1486UI, respectively).
Figure 2. Patient survey. Type of heparin administered
according to the haemodialysis technique employed
Statistically significant differences (P<.001).
LMWH: low molecular weight heparin; HD: haemodialysis; 
OL-HDF: on-line haemodiafiltration; UFH: unfractionated heparin.
Table 3. Patient survey. Baseline characteristics. Type of heparin administered according to age, sex, diabetes, and
haemoglobin levels.
Global UFH LMWH P
Mean age (years) 64.3 (15.6) 65.7 (15) 62.8 (15.9) 0.015
(range: 19-92)
Sex (M/F) (%) 59.2/40.8 61/39 58/42 ns
Diabetes (%) 25.5 23.8 27.1 ns
Haemoglobin(g/dl) 12 (1.2) 12.1 (1.2) 11.9 (1.3) 0.012
LMWH: low molecular weight heparin; UFH: unfractionated heparin; F: female; ns: not significant; M: male.
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As regards priming, 77.9% of patients that received oral
anticoagulants underwent heparin priming, with doses
similar to those of other patients.
Patients receiving anti-platelet treatment had no differences
from others in terms of the dose of heparin prescribed.
7. Anticoagulation and bleeding complications
Of the 743 patients analysed in this section, 33 (4.4%) had
experienced some type of bleeding complication within the
previous week of filling out the survey. We observed no
correlations between bleeding complications and age, sex,
diabetes, or anti-platelet treatment. Patients with bleeding
complications had significantly lower haemoglobin levels than
patients that did not (10.9±1.4g/dl vs 12.1±1.2g/dl; P<.001), and
received oral anticoagulation therapy more frequently (Figure 3).
If we eliminate patients that received oral anticoagulants from
the analysis, no significant differences were present in terms of
the number of bleeding complications between patients
receiving UFH and those receiving LMWH (P=.078).
8. Anticoagulation and thrombotic complications 
Thrombotic complications in the week prior to taking the
survey were reported in 14 of the 737 patients analysed
(1.9%), with a greater frequency of occurrence in patients
that received LMWH (P=.003). There were no significant
differences in the dose of heparin prescribed, whether UFH
or LMWH, between patients that experienced thrombotic
complications and those that did not.
Finally, of the 2 paediatric centres asked to participate, 1
provided the surveys for 2 patients. Both received LMWH
(enoxaparin), with heparin priming and high-flux HD using
polysulfone.
DISCUSSION
Firstly, we would like to point out that both surveys can be
considered valid for the analysis of our objectives. The
number of centres, the geographic distribution of the various
autonomous communities in Spain, the inclusion of both
public and private centres, and the number of patients treated
all lend strength to the haemodialysis centre survey. The
patient survey was bolstered by the random selection of
patients, lending similar characteristics to our sample as in
other recent studies such as the Dopps III, which was
considered representative of the adult Spanish population on
dialysis.13 As such, the mean age, sex distribution, proportion
of diabetic patients, mean haemoglobin values, and
distribution of the different types of vascular accesses used
are comparable between these studies.13
The primary objectives of our study were to assess the
anticoagulation methods employed in Spain and what
criteria they are based on. The near-50% distribution of
the two types of heparin, despite the guideline
recommendations that favour LMWH,12 indicate that, in
clinical practice, there are additional criteria taken into
account. Based on the type of data compiled, we cannot
completely verify the reason for the lower frequency
with which LMWH is used at private centres, even
though availability was similar. The issue of costs could
be an important factor; however, only 10% of centres
indicated that cost was taken into account when deciding
upon treatment. Whereas the greater costs of LMWH
limited its use in the past, this currently does not appear
to be an important limiting factor, with other criteria
taking precedent in deciding upon whether to prescribe
this drug.2
The risk of bleeding is the primary secondary side effect of
anticoagulation therapy in HD. In our study, there was no
association between bleeding complications and the type of
heparin administered, which confirms previous observations
that indicated a similar level of safety for both UFH and
LMWH.6,7 We are not aware of the reason for the greater
frequency of thrombotic complications observed in the group
receiving LMWH. The possible reasons include a lower
efficacy of this drug, inferior dosage adjustment, or the fact
that LMWH was prescribed more frequently in complex
patients with a greater tendency towards coagulability.
Figure 3. Patient survey. Treatment with oral
anticoagulants in patients with and without bleeding
complications in the previous week.
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Medical criteria, followed by ease of administration, were
the most commonly reported reasons for indicating LMWH.
In addition to bleeding and thrombotic phenomena,
dyslipidaemia,14 osteoporosis,15 and thrombocytopenia16-19 are
the most common side effects observed in the use of heparin
in HD patients, and were surely considered within the
medical criteria used to decide upon the prescription of
LMWH in the patients included in our study. Several studies
have demonstrated a lower increase in triglyceride levels in
HD patients with LMWH than in those receiving
UFH,8,9,14,20,21 although other studies did not corroborate with
these findings.22-24 On the other hand, in patients without
renal failure receiving prolonged treatment, the risk of
developing osteoporosis is lower when utilising LMWH
instead of UFH.15,25,26 In HD, LMWH has also been reported
to cause osteoporosis at a lower rate than UFH,11,27 although
no studies have clearly confirmed this phenomenon. Finally,
in the population without renal failure, the incidence of
thrombocytopenia induced by type II heparin is lower with
LMWH than UFH,28,29 which has also been described in
patients on HD.10
Both the survey for HD centres and the patient survey
revealed that the type of vascular access was the third most
common indication for employing LMWH. Although one
study did show that the permeability of vascular accesses
improves with the use of LMWH,30 to our knowledge, there
are no studies that have shown any advantages from using a
certain type of heparin over another when using autologous
AVF or prosthesis.
The dialysis technique used was also one of the criteria
employed for deciding whether to administer LMWH, which
was prescribed at a greater rate than UFH in OL-HDF. On
the other hand, the dose of LMWH was not significantly
different when comparing between OL-HDF, low-flux HD,
and high-flux HD. These data appear to contradict our
understanding of the pharmacokinetics of LMWH during
HD sessions. Several studies have shown that anti-Xa
activity is significantly reduced in high-flux HD and
convective techniques, as a consequence of the elimination
of LMWH through the dialysate/ultrafiltrate. McMahon et al.
showed that the anti-Xa activity in high-flux HD was lower
than in low-flux HD when using the same dose of
enoxaparin.31 Using continuous HD techniques, Isla et al.
demonstrated significant enoxaparin losses in the
ultrafiltrate/dialysate.32 Another study showed that anti-Xa
activity at the end of the HD session was significantly lower
on OL-HDF than low-flux HD.33 In any case, LMWH losses
in dialysate are higher at the start of an HD session when
administering boluses through the arterial branch of the HD
system.10 For these reasons, in high-flux HD and even more
so in HF and HDF techniques, some authors recommend
administering LMWH at the start of the HD session in the
venous branch of the extracorporeal blood circuit,10 or to
administer it 3-4 minutes before starting dialysis.34 In our
study, we did not analyse what type of administration was
used (arterial or venous branch) or the moment of
administration, since these questions were not included in
the surveys.
As regards the type of material used in HD, platelet
activation and coagulation varies according to the membrane
used, such that the following sequence can be established
based on these properties: unmodified cellulose membranes
> unmodified AN69 > polysulfone > polyamide.35 In our
study, we observed that the type of membrane used was not
correlated with the type of heparin or dosage used in normal
clinical practice. However, we must keep in mind that the
majority of these patients were treated using synthetic
membranes, primarily polysulfones/polyethersulfones.
It is interesting to point out that in patients receiving
LMWH, the blood pump flow was significantly lower than
in patients receiving UFH. Given that pump flow is directly
related to heparin dose, these results should be interpreted
taking into account that, given a higher risk of coagulation
from a lower pump flow, LMWH tends to be used, probably
with the goal of increasing efficacy, which would partly
explain the greater incidence of thrombotic phenomena
observed in this group.
Diabetes did not affect the use of heparin, neither type nor
dose, which is in accordance with the current clinical mind-
set that has rejected the antiquated and unproven idea that
heparinisation in dialysis could increase the risk of ocular
bleeding complications in these patients, which could
worsen the prognosis of diabetic retinopathy.
The majority of dialyser producers recommend dialyser and
circuit priming with saline solution and UFH, with the
generally accepted standard dose of 5000UI, regardless of
which type of heparin will be used in the HD session.36
However, in clinical practice, a significant percentage of HD
centres in Spain do not employ heparin priming, especially
when LMWH is used as an anticoagulant. Some next
generation HD machines allow for priming with the
dialysate fluid itself, removing the need for heparin, which
reduces costs and simplifies the procedure. In the survey for
HD centres, the dose used for heparin priming varied widely,
which implies great heterogeneity in the anticoagulation
practices within our country.
The surveys clearly show that dosing adjustments are for
the most part made through trial and error, and that
methods for measuring coagulation states in patients are
rarely used. Due to the design of the survey, we do not
know the reason for which 5.9% of centres determined an
anti-Xa factor for adjusting LMWH dose. One of the
possible indications is pre-HD measurements in patients
with a daily dialysis regimen, where there is an evident
risk of accumulation.35
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In our study, we observed that over half of all patients
on HD were also receiving treatment with oral
anticoagulants and/or anti-platelets. Few previous
studies have analysed this factor in prevalent HD
patients. In the DOPPS study, approximately 30% of
patients on dialysis took aspirin.37 In another analysis
from one single centre, 25% of patients were
receiving oral anticoagulants.38 An American study
involving 41 425 incident patients on HD showed that
8.3% received warfarin, 10% clopidogrel, and 30.4%
aspirin, and that the risk of death and hospitalisation
from bleeding was greater in patients that received
warfarin and clopidogrel, but not aspirin.39 Elliott et
al.,40 in a systematic review of 28 publications,
concluded that warfarin doubled the risk of severe
bleeding in HD patients. These results coincide in part
with our own, where there was a correlation between
the appearance of bleeding complications and
treatment with oral anticoagulants, and not with anti-
platelets, although we do not know what proportion of
patients were receiving aspirin or other anti-platelets.
The results from our surveys show that the majority of
patients receiving oral anticoagulants required heparin
during the dialysis session, which coincides with previous
observations.41 With this in mind, we can make the general
inference that oral anticoagulation is insufficient for
preventing system coagulations in HD. Even so, our study
produced the striking result that, while patients with oral
anticoagulation had UFH prescriptions that were adjusted
to lower amounts, this did not occur when LMWH was
used, and these doses were not different between the two
groups of patients.
As a final conclusion, there is a lack of general
accordance in terms of which aspects are important for
anticoagulation in patients on HD, such as which type of
heparin to use (UFH vs LMWH), the method of
administration for UFH (continuous or intermittent), the
use of heparin and doses for priming, the methods for
adjusting dosage, and the type of heparin to use based on
the dialysis technique. As such, there is a notorious
disparity in the criteria used in general daily practice for
prescribing anticoagulation treatment in patients on HD,
which necessitates a review of the results produced at
each centre and on the national level, and possibly the
creation of a guideline for anticoagulation in
haemodialysis.
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